Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
NeuPath HealthTSXV:NPTH 39 Debt-to-EBITDA is 2.08 as of Jun. 2026, which is 38% below its 10-year median of 3.38. GuruFocus rates TSXV:NPTH with a GF Score™ of 39/100 and a GF Value™ of C$0.25 (Significantly Overvalued). The stock has 2 warning signs investors should review. Among 482 Healthcare Providers & Services companies, NeuPath Health ranks worse than 64.11% on this metric.
Debt-to-EBITDA measures a company's ability to pay off its debt.
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
The historical rank and industry rank for NeuPath Health's Debt-to-EBITDA or its related term are showing as below:
TSXV:NPTH'
s Debt-to-EBITDA Range Over the Past 10 Years
Min: -24.26 Med: 3.38 Max: 22.97
Current: 3.33
During the past 7 years, the highest Debt-to-EBITDA Ratio of NeuPath Health was 22.97. The lowest was -24.26. And the median was 3.38.
TSXV:NPTH's Debt-to-EBITDA is ranked worse than 64.11% of 482
companies
in the Healthcare Providers & Services industry
Industry Median: 2.185
vs TSXV:NPTH: 3.33
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.
According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
NeuPath Health Debt-to-EBITDA Related Terms
NeuPath Health Debt-to-EBITDA Historical Data
* Premium members only.
The historical data trend for NeuPath Health's Debt-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TSXV:NPTH vs HCA, THC, DVA: Debt-to-EBITDA Comparison
For the Medical Care Facilities subindustry, NeuPath Health's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
NeuPath Health Debt-to-EBITDA vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, NeuPath Health's Debt-to-EBITDA distribution charts can be found below:
* The bar in red indicates where NeuPath Health's Debt-to-EBITDA falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data,
the EBITDA data used here is four times the quarterly (Jun. 2026) EBITDA data.
NeuPath Health (TSXV:NPTH) has a Debt-to-EBITDA of 2.08 as of Jun. 2026. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on NeuPath Health. This is 38% below median its historical median of 3.38. According to the industry distribution chart, NeuPath Health ranks #309 out of 482 companies in the Healthcare Providers & Services industry, placing it in the top 64.1%.
Is NeuPath Health's Debt-to-EBITDA too high?
NeuPath Health's current Debt-to-EBITDA of 2.08 is 38% below median its 10-year median of 3.38. The Healthcare Providers & Services industry median Debt-to-EBITDA is 2.19. NeuPath Health's value of 2.08 is 4.8% below this industry median. Based on the distribution chart, NeuPath Health ranks #309 out of 482 companies in the Healthcare Providers & Services industry, which is below the industry midpoint. Overall, NeuPath Health has a GF Score™ of 39/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does NeuPath Health's Debt-to-EBITDA compare to HCA and THC?
According to the Healthcare Providers & Services industry distribution chart, NeuPath Health ranks #309 out of 482 companies for Debt-to-EBITDA. This places NeuPath Health in the lower half of its industry. The industry median Debt-to-EBITDA is 2.19. NeuPath Health's value of 2.08 is 4.8% below this benchmark. While the company's 10-year median is 3.38 vs. the industry median of 2.19, NeuPath Health has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-EBITDA for a Healthcare Providers & Services company?
The median Debt-to-EBITDA among Healthcare Providers & Services companies is 2.19, based on 482 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. NeuPath Health's current Debt-to-EBITDA of 2.08 is 4.8% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-EBITDA mean?
A high Debt-to-EBITDA can signal that a stock is expensive relative to its fundamentals. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on NeuPath Health. For the Healthcare Providers & Services industry, the median Debt-to-EBITDA is 2.19 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. NeuPath Health's current Debt-to-EBITDA is 2.08, which is 38% below median its own 10-year median of 3.38. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is NeuPath Health stock overvalued right now?
Based on GuruFocus' analysis, NeuPath Health (TSXV:NPTH) is currently considered Significantly Overvalued. The stock's GF Value™ is C$0.25, compared to a current price of C$0.55 — trading 120% above its estimated fair value. The current Debt-to-EBITDA is 2.08, which is 38% below median its 10-year median of 3.38 and 4.8% below the Healthcare Providers & Services industry median of 2.19. NeuPath Health's overall GF Score™ is 39/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-EBITDA calculated?
Debt-to-EBITDA is calculated from a company's financial statements. For NeuPath Health (TSXV:NPTH), the current Debt-to-EBITDA is 2.08 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is NeuPath Health (TSXV:NPTH) Overvalued in 2026?
Based on GuruFocus' analysis, NeuPath Health stock appears to be overvalued.
The current stock price of C$0.55 is trading 120% above its estimated GF Value™ of C$0.25.
GuruFocus considers NeuPath Health to be Significantly Overvalued.
Key valuation signals for TSXV:NPTH:
Debt-to-EBITDA: 2.08 (38% below median its 10-year median of 3.38)
GF Value™: C$0.25 vs. price of C$0.55 (120% above fair value)
Industry Position: 4.8% below the Healthcare Providers & Services median (#309 of 482)
No single metric tells the full story. See the TSXV:NPTH stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
NeuPath Health Inc operates an end-to-end, integrated network of healthcare businesses. It utilizes research, data-driven insights, technology, and interdisciplinary care to help restore function for patients impacted by acute and chronic musculoskeletal conditions, including chronic pain, spinal injuries, sports-related injuries, and concussions. It operates an interdisciplinary network of medical clinics in Ontario and Alberta, in addition to an independent medical assessment business with a national network of healthcare providers. Its medical clinics provide comprehensive assessments and rehabilitation services to clients with chronic pain, musculoskeletal or back injuries, sports-related injuries, and concussions. The company operates in one industry segment: medical services.
39GF Score
Get the complete analysis for TSXV:NPTH
Debt-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSXV:NPTH has been successfully added to your 
